Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Marbl Melts
- Development stage
- Unknown
- Lead developer
- NeutriSci International
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Marbl Melts is a Cryopharm cannabis-infused, rapidly dissolving oral-melt product line. Public product materials describe micro-dosed melts formulated with THC, while historical launch materials described THC and CBD formulations; the line has included variants positioned for sleep, relaxation, and energy use. THC is expected to mediate its principal pharmacology through partial agonism of cannabinoid receptors, especially cannabinoid receptor 1 in the central nervous system. ([cryopharm.com](https://cryopharm.com/products/))
- Brand names
- Marbl MeltsMarbl Micro Melts
02
Targets
CNR1 (Cannabinoid receptor 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on Marbl Melts.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Marbl Melts.